Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial

JAMA

Volumn 282, Issue 24, 1999, Pages 2305-2312

  Kahn, James ^a,f   Lagakos, Stephen ^g   Wulfsohn, Michael ^g   Cherng, Deborah ^g   Miller, Michael ^g   Cherrington, Julie ^g   Hardy, David ^g   Beall, Gildon ^b   Cooper, Richard ^c   Murphy, Robert ^e   Basgoz, Nesli ^d   Ng, Edmund ^g   Deeks, Steven ^a   Winslow, Dean ^g   Toole, John J ^g   Coakley, Dion ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c Kraus Medical Partners   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; CARNITINE; LAMIVUDINE; PLACEBO; VIRUS RNA; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033596267     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.24.2305     Document Type: Article

References (32)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al, for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland: Swiss HIV Cohort Study. AIDS. 1998;12:1195-1201.
3. Brettle RP, Wilson A, Povey S, et al. Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients. Int J STD AIDS 1998;9:80-87.
4. Fleming PL, Ward JW, Karon JM, Hanson DL, De Cock KM. Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS. 1998; 12:S55-S61.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
6. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1997;351:543-549.
7. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283-291.
8. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081-1090.
9. Gazzard B, Moyle G, for the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet. 1998;352:314-316.
10. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
11. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Morb Mortal Wkly Rep. 1998; 47:43-82.
12. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-1300.
13. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94:13193-13197.
14. Balzarini J, Zhang H, Herdewijn P, Johns D, De Clercq E. Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxy) adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci U S A. 1991;88:1499-1503.
15. Bronson JJ, Kim CU, Ghazzouli I, Hitchcock MJM, Kern ER, Martin JC. Synthesis and antiviral activity of phosphonylmethoxyethyl derivatives of purine and pyrimidine bases. Am Chem Soc Symp. 1989;401:72-87.
16. Neyts J, Stahls F, Bruggeman C, De Clercq E. Activity of the anti-HIV agent 9-(2-phosphonylmethoxyethyl)-2-6-diaminopurine against cytomegalovirus in vitro and in vivo. Eur J Clin Microbiol Infect Dis. 1993; 12:437-446.
17. Balzarini J, Perno CF, Schols D, De Clercq E. Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/ macrophages and peripheral blood lymphocytes. Biochem Biophys Res Commun. 1991;178:329-335.
18. Kramata P, Votruba I, Otová B, Holt A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol. 1996;49: 1005-1011.
19. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res. 1987;8:261-272.
20. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. Human immunodefidency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capacity. J Infect Dis. 1999;179:92-100.
21. Barditch-Crovo P, Toole J, Hendrix CW, et al. Antihuman immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bispivaloyloxymethyl) phosphonylmethoxyethyl] adenine) in HIV-infected patients. J Infect Dis. 1997; 176:406-413.
22. Deeks SC, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel antihuman immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 1997;176:1517-1523.
23. Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet. 1989;2:469-473.
24. Bradley JV. Distribution-Free Statistical Tests. Englewood Cliffs, NJ: Prentice-Hall; 1968.
25. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
26. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley & Sons; 1980.
27. Bailar JC III, Mosteller F. Medical Uses of Statistics. 2nd ed. Boston, Mass: NEJM Books; 1992.
28. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS. 1991;5: 137-144.
29. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989;246:1155-1158.
30. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992;89:1934-1938.
31. Katlama C, Clotet B, Plettenberg A, Purdon S, Goh L, Cutrell A, for the CNA3002 International Study Team. Intensification of stable background antiretroviral therapy with Abacavir (ABC, 1592): 16 week data. In: Program and abstracts of the 4th International Congress on Drug Therapy in HIV Infection; November 8-12, 1998; Glasgow, Scotland. Abstract 66.
32. Gallant J, Beal J, Myers R, et al. Randomized, double-blind study of adefovir dipivoxil (ADV) at two dose levels in combination with nucleoside reverse transcriptase inhibitors (NRTI) and protease inhibitors (PI) for NRTI-experienced PI-naïve patients. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 1976.